IMMEDIATE BUY: Ventana Biotech (VNTA)

Ventana Biotech (VNTA) is rocking the anti-obesity segment of the health care industry with news of a chewing gum that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not.

Royalty cash flow from an anti-obesity drug is estimated at $1.5 to $1.7 billion a year.

Holding the key to this billion-dollar medical breakthrough is a young, under-the-radar biotech in England, Ventana Biotech. Trading symbol VNTA.


Imagine the buying frenzy created by a chewing gum that makes you thin.
Better yet, imagine the money you can make when you're one of the select individual investors able to get in early on the biotech stock making it happen.

Ventana Biotech's secret is found in the targeted hormonal triggers that are released with every chew... they tell your body you're full, even when you're not.

Practically everyone I know would run through a brick wall to get their hands on Ventana's product -- millions of us want lose weight. Unfortunately, millions more MUST lose weight, or die.

I'll bet you or someone you know has a friend who is either seriously overweight and in serious health danger, or clinically obese and in immediate health danger.

Well, your friends are not alone.

Obesity in America is epidemic. As many as 192 million Americans (about 66% of the population) are seriously overweight... clinically obese... and worse.

Obesity no longer waits for its victims to reach middle age. The disease is infecting children now -- at alarming rates.

Obesity kills -- more than 377,000 Americans were buried last year as a direct result of obesity. But health care professions know that obesity is far more deadlier than that.

Obesity leads the way to diabetes (more about that in a moment), and a long list of conditions that all lead to fatal heart disease.

And it's not just here in America. What's causing obesity's pandemic spread is a story better told another day. This report is for individual investors interested in the profits promised by effective treatments.

The only thing that gets fat is your wallet

Buy Ventana Biotech. This is a young company in England on the verge of grabbing a giant share of the $60-billion devoted to obesity, or I should say, devoted to eliminating obesity. The trading symbol is VNTA. The money you can make buying this stock today could change your life. Here's how... Ventana Biotech is rocking the anti-obesity industry with news of a chewing gum -- yes, chewing gum -- that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not. Pre-trial testing for FDA approval is now getting into gear. Buy VNTA now! The first commercial application of the "targeted hormonal triggers" to hit the market will likely be injectable and administered by doctors. This alone would be enough to lift VNTA shares to soaring heights. Ventana Biotech could be hauling in anywhere from $1.5 to $1.7 billion on this obesity treatment. There's more. The company's proprietary flagship product will treat not just obesity but also could treat Type-II diabetes. Even more amazing than this medical breakthrough is the amount of money you can make buying VNTA shares today. A modest $5,000 buy could balloon to $45,000 or more inside a year. Those who buy now stand to make the most money. Big pharma is dying to get its hands on this ground breaking anti-obesity treatment -- because billions of dollars are at stake. News of the royalty cash flow set to flood Ventana Biotech -- estimated at $1.5 to $1.7 billion -- can quickly TRIPLE the value of this still young $37 million company. Ventana Biotech conducts R&D without burning through cash, virtually eliminating financial risk to the company and its shareholders Ventana's miracle treatment works its magic without subjecting patients to dangerous side effects or adverse reactions... a welcome relief for patients and healthcare professionals alike. And now this revolutionary anti-obesity breakthrough is also being studied as a treatment for patients with Type II diabetes

Morgan Stanely estimates the market for drugs combating Type II diabetes to be in excess of $35 billion by 2012. Put Ventana Biotech in your portfolio right now. You can get it for under a buck. I'm telling readers to buy up to $3.00 for awesome profits. I'm telling you to buy VNTA today so you can make a fast TRIPLE BEFORE we even reach the buy limit. If you've been following stocks -- particularly biotech stocks -- then you know new drugs and speculation surrounding them can often move stocks by huge percentages in a single trading session. Beat Wall Street to Massive Profits Ventana Biotech is such a young company ($37 million market cap), and since it is in England (but traded publicly here in the US under the symbol VNTA), the company is off Wall Street's radar screens. Most investors don't even know this blockbuster exists. Driving Ventana -- and your investment profits -- is the company's proposed Anti-Obesity Chewing Gum (it doesn't have a fancy brand name yet). Early indications show the Gum safely reduces appetite by 15% to 25% and Ventana continues to perfect their biotechnology.

Royalty cash flow in the billions

Pre-trial testing for FDA approval is getting into gear -- and exclusive licensing of the product to Big Pharma is just around the corner.

Royalty cash flow from a successful anti-obesity drug is conservatively estimated at $1.5 to $1.7 billion a year. That's big money for any company. For a company the size of Ventana Biotech, the money is huge.

And there's more.

Once approved in the US by the FDA, Ventana's anti-obesity chewing gum will be included among 10 other competing oral therapies for diabetes as well.

FDA approval seems a lock since Ventana's proprietary product is entirely safe.* It contains an extract of hoodia gordonii and 2-hydroxyoleic acid.
* Please note that this product has not been approved by the FDA.

Hoodia gordonii is a leafless, catus-like plant that grows wild in Southern Africa. Native populations used the plant for hundreds of years to suppress appetite on long hunting trips in the Kalahari Desert.

Now modern science discovers the plant also possesses the ability to lower blood glucose levels, thereby also thrusting Ventana Biotech's anti-obesity product into the limelight for treatment and prevention of diabetes as well.

But first, you stand to make a fortune defeating obesity.

Here's how the miracle works

The active ingredients in the plant extracts are released into the patient's blood stream and trigger a hormonal response in the part of the brain (the hypothalamus) that tells you, "I'm full."

And because the plant extracts activate a hormone that naturally exists in the body -- it's naturally produced every time you finish a meal -- there are no harmful side effects.

Buy VNTA now -- get in under a buck!

Ventana Biotech belongs in your portfolio right now. You can get shares for under a buck. I'm telling readers to buy up to $3.00 for awesome profits. I'm telling you to get VNTA today so you can make a fast TRIPLE BEFORE we even reach the buy limit.

A modest $5,000 investment in VNTA looks to zoom to $19,230 -- before the stock climbs to my $3 buy limit... then to $23,076 when the buy target is meet... and then from there, onwards and upwards even higher.

I expect you'll make so much money on VNTA alone that you'll want regular profit alerts from me as a subscriber to my newsletter.

Each year I put out a Winning Stocks Report and since 2004, clients who bought the stocks absolutely trounced the market.

You might also be interested to know since 2004, clients who bought the stocks I recommended in my annual Winning Stocks special report absolutely trounced the market. In 2007, for example our Winning Stock recommendations ended the year with a stunning 51.8%---a huge win when you consider the Dow was up only 6.4%

Wentworth Energy Suncor Energy Genzyme Pharma Product Dev

+1,000% +346% +256% +196%

Nova Gold Advanced PSC Petro China U.S. Global

+135% +102% +100% +100%